International Planned Parenthood Federation (IPPF) responds to new World Health Organization (WHO) antiretroviral treatment guidelines recommending dolutegravir (DTG)-based treatment for women and girls. The drug’s high success rate has led to DTG rollout in many countries for people living with HIV globally than other current first-line treatment options. IPPF is concerned the guidelines could result in women living with HIV being coerced to use contraception or take less effective HIV treatment options.

For further information: https://www.ippf.org/news/no-coercion-treatment-options-women-living-hiv